Search Results

Results 181 - 190 of 791 for stem cells. (3.54 seconds)
  • Magazine examines art’s role in medicine

    When the arts and humanities play a role in medicine, patients, researchers and doctors can benefit. The winter issue of Stanford Medicine magazine features articles on the intersection of medicine with the arts and humanities.

  • Listening to the brain

    Stanford engineers and neurosurgeons have worked together to develop an experimental technology that could one day allow people with paralysis to affect the world around them using only their minds.

  • Pancreatic cells change fate to produce insulin

    Alpha cells can convert to insulin-producing beta cells in mice when just two genes are blocked, a new Stanford study shows. A similar mechanism may occur in people with diabetes.

  • Heart-damaging chemo drugs ranked

    Stanford researchers have developed a test that may help screen for cardiotoxicity in new chemotherapy drugs.

  • 15 faculty named CZ Biohub investigators

    The researchers will be given funding by the Chan Zuckerberg Biohub to develop tools and technologies that support the organization’s goal of curing, preventing or managing every disease.

  • 1 cent ‘lab on a chip’

    Microfluidics, electronics and inkjet technology underlie a newly developed all-in-one biochip from Stanford that can analyze cells for research and clinical applications.

  • Scientists awarded stem cell grants

    The grants to Stanford researchers target stem cell-based therapies for autoimmune disorders, liver disease and cystic fibrosis.

  • Rat-grown pancreases help save diabetic mice

    Growing organs from one species in the body of another may one day relieve transplant shortages. Now researchers show that islets from rat-grown mouse pancreases can reverse disease when transplanted into diabetic mice.

  • Five faculty members elected to ASCI

    Ash Alizadeh, Maximilian Diehn, Brian Feldman, Aida Habtezion and Ravindra Majeti were elected to the medical honor society.

  • Tumor rejection requires coordinated immune response

    Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. A Stanford study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.